Refine
Has Fulltext
- yes (27)
Is part of the Bibliography
- yes (27)
Year of publication
Document Type
- Journal article (27)
Language
- English (27)
Keywords
- T cells (4)
- GvHD (2)
- Multiple myeloma (2)
- alloreactive T cells (2)
- cancer (2)
- immune cells (2)
- mouse models (2)
- regulatory T cells (2)
- Activation (1)
- Allogeneic stem cell transplantation (1)
- Alpha therapy (1)
- Aspergillus (1)
- Autoimmune diseases (1)
- B cells (1)
- BRAF mutation (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- CD11b+ myeloid cells (1)
- CNS cancer (1)
- CRISPR/Cas9 (1)
- Cancer treatment (1)
- Capicua transcriptional repressor (1)
- Drug resistance (1)
- Expression (1)
- Extramedullary disease (1)
- Factor receptor (1)
- Fak regulation (1)
- GVHD (1)
- Graft-versus-host disease (1)
- Graft-versus-leukemia (1)
- IRF4 (1)
- Immunology (1)
- Induced apoptosis (1)
- Infectious disease (1)
- Lichtheimia (1)
- Lymphomas (1)
- MPI (1)
- MPS (1)
- Mechanisms (1)
- Medizin (1)
- Migration (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Multiple (1)
- NF-Kappa-B (1)
- NFAT (1)
- NFATc1 (1)
- Parkinson's disease (1)
- Pathogenesis (1)
- Phase- (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Spleen (1)
- Stromal cells (1)
- Suppression (1)
- T-cell transfer (1)
- TNF (1)
- TNFR family costimulatory receptors (1)
- TNFR2 (1)
- TNFR2 agonists (1)
- TNFR2 antagonism (1)
- Tregs (regulatory T cells) (1)
- Trypanosoma (1)
- Tumor-necrosis-factor (1)
- VLA-1 (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- agonist (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- antigen-presenting cells (1)
- aspergillus fumigatus (1)
- autologous transplantation (1)
- biomarkers Myelomas (1)
- biophysics (1)
- bone imaging (1)
- bone marrow (1)
- bortezomib plus dxamethasone (1)
- brain tumor (1)
- calcofluor white staining (1)
- cancer microenvironment (1)
- cancer stem cells (1)
- cancer treatment (1)
- cell staining (1)
- cereblon expression (1)
- children (1)
- corticosteroids and cyclophosphamide (1)
- crosslinked coating (1)
- cytokines (1)
- cytotoxic T cells (1)
- elderly patients (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- fungal infection model (1)
- gRNA-only (1)
- gene regulation (1)
- graft vs. host disease (1)
- group 3 (1)
- homing (1)
- imaging agents (1)
- immune cell recruitment (1)
- immune control (1)
- immunotherapy (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- magnetic properties (1)
- megakaryocytes (1)
- mesenteric lymph node (1)
- metabolism (1)
- metastasis (1)
- microswimmer (1)
- monoclonal gammopathy (1)
- multiparameter flow-cytpmetry (1)
- multiple myeloma Lesions (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myeloma cells (1)
- naive T-cell gene editing (1)
- neuroimmunology (1)
- none (1)
- orthotopic xenograft (1)
- paediatric cancer (1)
- prediction (1)
- randomized phase-3 trial (1)
- serum retention (1)
- signal transduction (1)
- silkworm (1)
- sleeping sickness (1)
- spleen (1)
- stem-cell transplantation (1)
- structural biology (1)
- thalidomide maintenance (1)
- thrombopoiesis (1)
- transient regulatory T-cell targeting (1)
- transplantation (1)
- tsetse fly (1)
- tumour immunology (1)
- undetermined significance MGUS (1)
Institute
- Medizinische Klinik und Poliklinik II (25)
- Pathologisches Institut (7)
- Institut für Virologie und Immunbiologie (6)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (5)
- Kinderklinik und Poliklinik (5)
- Graduate School of Life Sciences (4)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Rudolf-Virchow-Zentrum (3)
- Neurochirurgische Klinik und Poliklinik (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 825575 (1)
Background
Acute graft-versus-host disease (aGVHD) poses a major limitation for broader therapeutic application of allogeneic hematopoietic cell transplantation (allo-HCT). Early diagnosis of aGVHD remains difficult and is based on clinical symptoms and histopathological evaluation of tissue biopsies. Thus, current aGVHD diagnosis is limited to patients with established disease manifestation. Therefore, for improved disease prevention it is important to develop predictive assays to identify patients at risk of developing aGVHD. Here we address whether insights into the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T cells before clinical aGVHD onset to permit for efficient therapeutic intervention.
Methods
Murine major histocompatibility complex (MHC) mismatched and minor histocompatibility antigen (miHAg) mismatched allo-HCT models were employed to assess the spatiotemporal distribution of donor T cells with flow cytometry and in vivo bioluminescence imaging (BLI). Daily flow cytometry analysis of peripheral blood mononuclear cells allowed us to identify migrating alloreactive T cells based on homing receptor expression profiles.
Results
We identified a time period of 2 weeks of massive alloreactive donor T cell migration in the blood after miHAg mismatch allo-HCT before clinical aGVHD symptoms appeared. Alloreactive T cells upregulated α4β7 integrin and P-selectin ligand during this migration phase. Consequently, targeted preemptive treatment with rapamycin, starting at the earliest detection time of alloreactive donor T cells in the peripheral blood, prevented lethal aGVHD.
Conclusions
Based on this data we propose a critical time frame prior to the onset of aGVHD symptoms to identify alloreactive T cells in the peripheral blood for timely and effective therapeutic intervention.